Grand River Aseptic Manufacturing is a parenteral contract manufacturer supporting new product development and small batch production. With a state‐of‐the‐art cleanroom and highly trained staff, Grand River Aseptic Manufacturing provides small scale clinical trial materials aseptically filled into vials and lyophilization for the pharmaceutical and biopharmaceutical markets.
Grand River specializes in pre‐clinical, phase I through III clinical trials, and small scale commercial production quantities. We offer the following services for clinical, small scale, and commercial‐stage products: Sterile product development and manufacture, Lyophilization, Terminal sterilization and Analytical and microbiological services.
Our Grand Rapids, Michigan facility includes:
Grand River specializes in pre‐clinical, phase I through III clinical trials, and small scale commercial production quantities. We offer the following services for clinical, small scale, and commercial‐stage products: Sterile product development and manufacture, Lyophilization, Terminal sterilization and Analytical and microbiological services.
Grand River Aseptic Manufacturing serves the global pharmaceutical and biopharmaceutical industries.
Innovation Michigan Finalist: Grand River Aseptic Manufacturing
Grand River Aseptic Gains FDA Registration
Visit us at: Booth 1342
If you would like to schedule a personal meeting during the 2011 AAPS show please call or email: Greg Gonzales at (240) 344-9412 / ggonzales@grandriverasepticmfg.com.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.